Rhinitis, Allergic, Perennial News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

New guidelines for allergic rhinitis change treatment - Pharmacy Today, American Pharmacists Association, pharmacist.com



New guidelines for allergic rhinitis change treatment 
Pharmacy Today, American Pharmacists Association, pharmacist.com
The Joint Task Force on Practice Parameters (JTFPP) has issued updated recommendations for the treatment of seasonal allergic rhinitis (SAR) in adolescents and adults. The new guidelines—which update guidance last issued in 2008—are ...

 


Allergic Rhinitis Drugs Market ? Research by Type, Application ... - Medgadget (blog)



Medgadget (blog)
 
Allergic Rhinitis Drugs Market ? Research by Type, Application ... 
Medgadget (blog)
HTF MI recently added a new research study in its database that highlights the in-depth market analysis with future prospects of Allergic Rhinitis Drugs.

and more » 


Is Concordia Hlth Cm (NASDAQ:CXRX) Oversold? - Highlight Press - Highlight Press



Is Concordia Hlth Cm (NASDAQ:CXRX) Oversold? - Highlight Press 
Highlight Press
The Relative Strength Index (RSI) is a very common technical indicator used to assess the strength and weakness of momentum in stock movements. RSI levels ...

and more » 


Man Who Turned Down Shark Tank's $4M Offer Kicks Off 40-Country Wide Distribution with a Purchase Order for $8M ... - Lawfuel (blog)



Lawfuel (blog)
 
Man Who Turned Down Shark Tank's $4M Offer Kicks Off 40-Country Wide Distribution with a Purchase Order for $8M ... 
Lawfuel (blog)
Nothing to Sneeze At, With 50% of the United States Population Being Affected and $365B Spent on Allergies Alone. NEW PORT RICHEY, Fla., Jan. 18, 2016 LawFuel? Entrepreneur Joe Moore was almost laughed off the stage while presenting his nasal ...

 


ENT Disorder Treatment Market Growth Analysis and Opportunity ... - MilTech



ENT Disorder Treatment Market Growth Analysis and Opportunity ... 
MilTech
ENT Disorder Treatment market research report is a compilation of insight data on market size, growth and.

and more » 


Allergic Rhinitis Treatment Market: Intravenous to Account US $1.25 Bn in 2024 - NB Herard



Allergic Rhinitis Treatment Market: Intravenous to Account US $1.25 Bn in 2024 
NB Herard
New York, NY ? (PRESS RELEASE JET) ? 10/25/2017 ? ?Technological advancements in the medical world and rising prevalence of foodborne diseases will primarily build the market for allergic rhinitis treatment globally. Secondarily, strategic ...

 


Concordia International Corp. (NASDAQ:CXRX) Oversold but Is That a Buy Indicator? - HugoPress



BangaloreWeekly
 
Concordia International Corp. (NASDAQ:CXRX) Oversold but Is That a Buy Indicator? 
HugoPress
... control of severe or incapacitating allergic conditions such as atopic dermatitis, and seasonal and perennial allergic rhinitis. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016.
Concordia International Corp. - CXRX - Stock Price Today - Zacks Zacks Investment Research

all 59 news articles » 


Concordia International Corp. (NASDAQ:CXRX) is Oversold Based on Its RSI - HugoPress



Concordia International Corp. (NASDAQ:CXRX) is Oversold Based on Its RSI 
HugoPress
... control of severe or incapacitating allergic conditions such as atopic dermatitis, and seasonal and perennial allergic rhinitis. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016.

and more » 


Concordia International Corp. (NASDAQ:CXRX) Oversold, but Is It Time to Buy? - First News 24



Thorold News
 
Concordia International Corp. (NASDAQ:CXRX) Oversold, but Is It Time to Buy? 
First News 24
... control of severe or incapacitating allergic conditions such as atopic dermatitis, and seasonal and perennial allergic rhinitis. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016.
7 Stocks of the Month: December Edition Zacks.com
Concordia International Corp. - CXRX - Stock Price Today - Zacks Zacks Investment Research

all 104 news articles » 


Sunovion Divesting US Market Rights to Asthma and Allergic Rhinitis Therapies to Covis Pharma - COPD News Today



Sunovion Divesting US Market Rights to Asthma and Allergic Rhinitis Therapies to Covis Pharma 
COPD News Today
Sunovion Pharmaceuticals will divest its U.S. market rights for ciclesonide products for the treatment of asthma and allergic rhinitis to Covis Pharma. With this agreement, Sunovion confirms its focus on chronic obstructive pulmonary disease (COPD ...